Interferon in the management of neuroendocrine GEP-tumors: a review.
about
Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cellsGuidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert GroupA novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidineRadiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience.Type I interferons inhibit the generation of tumor-associated macrophages.Carcinoid tumor of the appendix: a consecutive series from 1237 appendectomiesENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.Carcinoid syndrome: diagnosis and medical management.The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas.The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursIsolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastasesNon-functioning pancreatic neuroendocrine tumors--a case report and review of literature.Therapy of aggressive pituitary tumors.Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature.Translation of molecular pathways into clinical trials of neuroendocrine tumors.Non-functional pancreatic neuroendocrine tumor as an incidentaloma--a case report and review of literature.Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view.Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.The Essential Role of Type I Interferons in Differentiation and Activation of Tumor-Associated Neutrophils.Medical treatment of gastroenteropancreatic neuroendocrine tumors.Management of the hormonal syndrome of neuroendocrine tumors.Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment.[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.GOT1 xenografted to nude mice: a unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors.Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases.Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.Management of functional neuroendocrine tumors of the pancreas.[Metastatic neuroendocrine neoplasms. Non-surgical treatment strategies].Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
P2860
Q24300739-BC4AF9A6-8DF6-4F4E-BC82-8E862726F751Q24674315-F74E7F9B-5637-4D09-B2D9-4DC52BA1D9ECQ24799372-2E5FDA1E-275E-4065-BFEB-BBCC4F902329Q33212716-301D55D2-59A2-438D-B2B4-FBA79E2FCB13Q33943369-5440B423-79B6-458F-82D8-F9D04FD45509Q34017792-F3C287EC-20E6-4648-AE02-BF0199B3F631Q34248487-98AC6943-B0A9-42BC-9B7B-B8CFB50B08D3Q34301030-CEEE7C5F-2CAF-4419-9D49-0E442383CCA0Q34564262-ABE2176E-4F81-4468-86CC-F1FE6D7B285EQ36380878-6EECCAB8-480C-4A91-8A58-A880B6D85794Q36409960-E121828C-6C25-407F-AA95-7B11DFF23763Q36755905-997E4953-CD51-4DA8-A64F-8C9B8005167AQ36772465-D1D8C138-96FE-4067-88FB-2EEA7EB81606Q37802274-B1C624EC-6EB3-40AC-9102-9D3538DEF1EBQ37857296-1BB474DD-1717-4742-8C96-B6633E6724B7Q37880665-56405240-C19D-4B55-9CF7-A11F8C62B0C2Q38003074-C6869013-19DB-4C13-9648-46A0984D7E61Q38052101-D217D664-5CB0-4042-8C2F-D78EF2D5F834Q38412071-2A64B31A-C92B-416C-8E24-EF5C224DCACDQ38842250-498CB1E9-9D74-4CB7-A391-458C446B5B71Q39076005-4BED5B79-FAF4-449D-96B7-7C71472C4DB9Q39254045-D0804FA9-64F5-432A-A8EB-0ADDD59BD16BQ41832570-152F5537-35EA-4BE2-B019-9A47D4902F5EQ42359114-E812F408-5608-4B27-B77A-2B31835919E5Q42406543-3BAAE05F-8CD1-4FA2-95C1-564B2A5D22E3Q43196885-06905E21-156C-4338-A683-E7260DC97C37Q44056924-8A433187-9FB6-41ED-BBF9-623C8F0D338DQ44479307-D6768E8A-6517-444A-B5F0-A26DA0568F85Q44903225-FDDB6647-6B63-4C22-9510-AFE34CE84FC8Q46553758-D624F331-642B-425D-8A60-8F304A5E3661Q47886895-8033D956-3C7E-4511-B8EF-DF76B0AD2D5BQ51479301-B4F34033-09E4-426F-A63A-130340F014E2Q52599451-46F19EC0-ED1E-4B35-A2DB-CDF5401E3CDEQ52894194-00DBF2AA-B934-4FFA-99C3-7BCB466C414AQ52952533-1329871E-A017-4DA8-AE94-7683C0A4D999
P2860
Interferon in the management of neuroendocrine GEP-tumors: a review.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Interferon in the management of neuroendocrine GEP-tumors: a review.
@ast
Interferon in the management of neuroendocrine GEP-tumors: a review.
@en
Interferon in the management of neuroendocrine GEP-tumors: a review.
@nl
type
label
Interferon in the management of neuroendocrine GEP-tumors: a review.
@ast
Interferon in the management of neuroendocrine GEP-tumors: a review.
@en
Interferon in the management of neuroendocrine GEP-tumors: a review.
@nl
prefLabel
Interferon in the management of neuroendocrine GEP-tumors: a review.
@ast
Interferon in the management of neuroendocrine GEP-tumors: a review.
@en
Interferon in the management of neuroendocrine GEP-tumors: a review.
@nl
P356
P1433
P1476
Interferon in the management of neuroendocrine GEP-tumors: a review.
@en
P2093
P356
10.1159/000051862
P478
62 Suppl 1
P577
2000-01-01T00:00:00Z